RecruitingNCT06551129

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Real-World Camzyos Patient Reported OutcoMes Through PAtient SurveyS in Hypertrophic CardioMyopathy (COMPASS-HCM): A Prospective Longitudinal Study

Sponsor

Bristol-Myers Squibb

Enrollment

118 participants

Start Date

May 10, 2024

Study Type

OBSERVATIONAL

Conditions

Obstructive Hypertrophic Cardiomyopathy

Summary

This real-world study will assess changes in health status among participants with symptomatic obstructive hypertrophic cardiomyopathy who are treated with mavacamten in the real world.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Mavacamten for people with obstructive hypertrophic cardiomyopathy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.